Vanda Pharmaceuticals Inc. (VNDA): Shareholders' Equity
$327.19M
As of 2025-12-31
$220.19M
As of 2026-06-30
-14.7%
3-year compound annual growth
-6.3%
5-year compound annual growth
+9.4%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $327.19M | -39.2% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $538.55M | -1.2% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $544.91M | +3.4% | 2026-02-12, Balance as of period end |
| 2022-12-31 | $527.20M | +4.4% | 2025-02-14, Balance as of period end |
| 2021-12-31 | $504.93M | +11.4% | 2024-02-08, Balance as of period end |
| 2020-12-31 | $453.27M | +10.3% | 2023-02-09, Balance as of period end |
| 2019-12-31 | $410.94M | +49.2% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $275.42M | +109.6% | 2021-02-11, Balance as of period end |
| 2017-12-31 | $131.39M | 0.0% | 2020-02-26, Balance as of period end |
| 2016-12-31 | $131.33M | -1.3% | 2019-02-19, Balance as of period end |
| 2015-12-31 | $133.03M | -17.3% | 2018-02-15, Balance as of period end |
| 2014-12-31 | $160.82M | +264.5% | 2017-02-17, Balance as of period end |
| 2013-12-31 | $44.12M | +345.5% | 2016-02-12, Balance as of period end |
| 2012-12-31 | $9.90M | -70.4% | 2015-03-13, Balance as of period end |
| 2011-12-31 | $33.47M | -11.3% | 2014-02-25, Balance as of period end |
| 2010-12-31 | $37.73M | +63.8% | 2013-02-26, Balance as of period end |
| 2009-12-31 | $23.03M | n/a | 2012-03-09, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.02B | -3.4% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $130.34M | +41.5% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
Compare VNDA, AMRN, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗